Cardiovascular and electrocardiographic effects of iopentol in left ventricular angiography Comparison of the low-osmolar, non-ionic iopentol (Imagopaque® 350) and the hyper-osmolar, ionic metrizoate meglumine-Na-Ca (Isopaque® Coronar 370) in patients with coronary heart disease

Q2 · MEDICINE

Article

Author: K. Skinningsrud ; T. Haider ; A. Bjørkhaug ; R. Danielsen ; H. Vik-Mo

The aim of the study was to evaluate and compare the hemodynamic and electrocardiographic effects following injection of the non-ionic, low-osmolar contrast medium iopentol (Imagopaque 350, Nycomed Imaging AS, Oslo, Norway) and the ionic, hyper-osmolar contrast medium metrizoate meglumine-Na-Ca (Isopaque Coronar 370, Nycomed Imaging AS, Oslo, Norway) when used for left ventricular angiography. The study was performed in a double-blind, randomized manner in 82 patients with severe coronary heart disease. The patients who received iopentol experienced less adverse events and subjective discomfort of lesser intensity than those who received metrizoate (p = 0.0001). Both contrast media induced a biphasic change in left ventricular (LV) systolic pressure, with an initial fall followed by a prolonged rise, but the alterations were statistically significantly more pronounced with metrizoate than with iopentol. The changes in LV end-diastolic pressure (p = 0.023), and LV negative dP/dt (p = 0.002) were significantly more pronounced with metrizoate than with iopentol. Cardiac output and heart rate increased more with metrizoate, while stroke volume was equally increased by both agents. A prolonged increase in the QT-interval, throughout the 10-min observation period, was seen only after injection of metrizoate (p = 0.0006 for comparison between contrast media).CONCLUSIONIopentol was well tolerated and induced markedly less severe hemodynamic and electrocardiographic alterations than did metrizoate in patients with severe coronary heart disease.

01 Mar 1990·Acta RadiologicaQ4 · MEDICINE

Comparison of Non-Enhanced, Bolus Enhanced, and Delayed Scanning Techniques in Computed Tomography of Hepatic Tumours

Q4 · MEDICINE

Article

Author: Ulf Tylen ; Göran Tidebrant ; P. Lukes ; M. Asztely

Non-enhanced, bolus contrast medium enhanced and 4 to 6 hours delayed computed tomography of the liver was performed in a prospective study of 53 patients. Forty patients had focal lesions, in 12 of these they were hypervascular. Contrast medium was administered as an initial bolus followed by a rapid injection of meglumine metrizoate (Isopaque Cerebral). The total iodine dose varied between 56 and 63 g, which gave an average increase in attenuation of 14 HU in normal parenchyma comparing delayed with non-enhanced scanning. Presence and extent of focal lesions were evaluated in a randomized and independent analysis by two radiologists. The percentage of examinations with correct tumour description was higher with bolus scanning (observer I 73%, observer II 75%) and delayed scanning (observer I 75%, observer II 78%) than with non-enhanced scanning (observers I and II 67%). An optimal bolus technique requires an exact timing of the contrast medium administration and scanning. Delayed scanning provides an excellent supplement when the bolus examination is suboptimal or shows equivocal findings.

01 Jun 1988·Clinical Physiology

Glomerular filtration rate estimated from a single plasma sample after contrast‐enhanced radiological examinations

Article

Author: M. Boijsen ; L. Jacobsson ; Ulf Tylen

SummaryIn twenty‐six patients examined with radiographic procedures, including a single injection of meglumine metrizoate, blood samples were drawn 180,200,220 and 240 min after injection. Plasma was analysed for iodine concentration with X‐ray fluorescence analysis and the total plasma clearance of metrizoate was calculated with the single sample method from each sample.The results were compared with the total plasma clearance of 51Cr‐EDTA, calculated from multiple samples and determined no more than a few days apart from the X‐ray examination. A good correlation, ranging from 0·91 and 0·94, was found. We therefore conclude that kidney function can be estimated from a single plasma sample after contrast‐enhanced radiological examinations.

100 Deals associated with Calcium Metrizoate/Meglumine Metrizoate/Metrizoate Magnesium/Metrizoate Sodium

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Calcium Metrizoate/Meglumine Metrizoate/Metrizoate Magnesium/Metrizoate Sodium

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation